RePORT ⟩ RePORTER

Project Details

Preclinical Services for Biopharmaceutical Product Development

Project Number75N93023D00008-0-759302300001-2

Contact PI/Project Leader

Awardee OrganizationDYNPORT VACCINE COMPANY, LLC

Description

Abstract Text

The Biopharmaceutical Product Development Services program provides services to facilitate preclinical development of materials that are derived from biotechnology processes, such as monoclonal antibodies and derivatives of monoclonal antibodies; recombinant proteins; peptides; nucleic acid based vectors (siRNA, plasmids); and live, modified-live and/or attenuated entities. Services include: product development planning and evaluation; assay development and product characterization; process development and formulation; GMP manufacturing; and regulatory CMC documentation support. The aim is advance translational research for infectious diseases.

Public Health Relevance Statement

Data not available.

NIH Spending Category

BiotechnologyClinical ResearchHealth ServicesInfectious Diseases

Project Terms

AttenuatedBiological ProductsBiotechnologyDevelopmentDevelopment PlansDocumentationEvaluationFormulationInfectious Diseases ResearchMonoclonal AntibodiesNucleic AcidsPeptidesPlasmidsProcessRecombinant ProteinsServicesSmall Interfering RNATranslational Researchassay developmentmanufacturepre-clinicalpreclinical developmentproduct developmentservice programsvector

Details

Other PIs

Not Applicable

Program Official

Name

Contact

Email not available

Organization

Name

DYNPORT VACCINE COMPANY, LLC

City

FREDERICK

Country

UNITED STATES (US)

Department Type

Unavailable

Organization Type

Domestic For-Profits

State Code

Congressional District

Other Information

Opportunity Number

Study Section

Fiscal Year

2023

Award Notice Date

Administering Institutes or Centers

National Institute of Allergy and Infectious Diseases

CFDA Code

DUNS Number

014130053

UEI

LXNEGTYDR755

Project Start Date

08-September-2023

Project End Date

07-September-2030

Budget Start Date

Budget End Date

Project Funding Information for 2023

Total Funding

$1,079

Direct Costs

Indirect Costs

Year	Funding IC	FY Total Cost by IC
2023	National Institute of Allergy and Infectious Diseases	$1,079

NIH Categorical SpendingClick here for more information on NIH Categorical Spending

Funding IC	FY Total Cost by IC	NIH Spending Category
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES	$1,079	Biotechnology; Clinical Research; Health Services; Infectious Diseases

Sub Projects

No Sub Projects information available for 75N93023D00008-0-759302300001-2

Publications

Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.

No Publications available for 75N93023D00008-0-759302300001-2

Patents

No Patents information available for 75N93023D00008-0-759302300001-2

Outcomes

The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.

No Outcomes available for 75N93023D00008-0-759302300001-2

Clinical Studies

No Clinical Studies information available for 75N93023D00008-0-759302300001-2

News and More

Section Menu